
CLAIMS

What is claimed is:

1. A compound having the structure of Formula **I**:



I

wherein

R^1 is independently –H, –OH, –O-C(O)-R^8 or –F,

R^2 is independently –H, –OH, –O-C(O)-R^8 or –F,

R^3 is –OH, or –O-C(O)-R^8,

R^4 is –H, –OH, –O-C(O)-R^8 or –(C_1-C_8)alkyl,

wherein R^3 and R^4 can be in the form of a carbonyl oxygen (=O),

R^5 is –H, –OH, –O-C(O)-R^8 ,–(C_1-C_8)alkyl, -O-(C_1-C_8)alkyl, -NH_2 or -NHR^8

wherein R^4 and R^5 can form a 3-6 membered cycloalkyl ring,

R^6 is –H, –(C_1-C_8)alkyl, –C(H)=CH_2, –C(H)=CH(C_1-C_8)alkyl), –C(H)=C(C_1-C_8)alkyl)(C_1-C_8)alkyl), –C(H)=C=CH_2, –C(H)=C=C(C_1-C_8)alkyl)H, –CH_2C≡CH, –OH or –O(C_1-C_8)alkyl,

R^7 is –H, –OH, –OCH_3, –SH or –Cl,

R^8 is independently –(C_1-C_8)alkyl, aryl, –(CH_2)$_n$(aryl), heteroaryl or –(CH_2)$_n$(heteroaryl),

n is an integer 1, 2, 3, 4 or 5,

wherein at least one R^4 or R^5 is not –H.

wherein each alkyl, cycloalkyl, aryl and heteroaryl are independently optionally substituted by one or more of CN, NO_2, halogen, (C_1-C_3)alkyl, (C_1-C_3)haloalkyl, (C_1-C_3)cycloalkyl, aryl,

heteroaryl, OH, alkenyl, alkynyl, O-(C_1-C_3)alkyl, O-C(O)-R^9, O-(alkylene)aryl, O-(alkylene)heteroaryl, C(O)R^9, S(C_1-C_8)alkyl, S(O)(C_1-C_8)alkyl, SO_2(C_1-C_8)alkyl, C(O)OR^9, C(O)NR^9R^9, C(O)NR^9SO_2(C_1-C_8)alkyl, NR^9R^9, NR^9(CO)OR^9, NH(CO)R^9, NH(SO_2)(C_1-C_8)alkyl or NH(SO_2)NR^9R^9, and R^9 is independently –H, –OH, –(C_1-C_8)alkyl, cycloalkyl, heterocyclyl, or the two R^9's of C(O)NR^9R^9 or NR^9R^9 combine together with the nitrogen atom to form a heterocycle;
or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein R^1 and R^2 are –H, –OH, or F, or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1, wherein R^3 is –OH or –O-C(O)-CH_3, or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1, wherein R^4 is –H or –(C_1-C_8)alkyl, or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1, wherein R^4 is –H or –CH_2CH_3, or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1, wherein R^5 is –H or –(C_1-C_8)alkyl, or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.





















7. The compound of claim 1, wherein R^6 is –C(H)=CH_2 or –CH_2C≡CH, or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1, wherein R^7 is –H or –OH, or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1, wherein R^8 is –(C_1-C_8)alkyl, or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1, wherein R^8 is –CH_3, or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1, wherein the compound is selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

, and


or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising one or more compounds of claim 1, or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

13. A compound of claim 1, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of ~~A method for treating or preventing~~ an infectious disease or cancer~~, the method comprising administering to the individual an effective amount of one or more compounds of claim 1, or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof~~.

14. The compound for use~~method~~ of claim 13, wherein the infectious disease is a viral infection.

15. The compound for use~~method~~ of claim 14, wherein the viral infection is infection with a virus selected from the group consisting of HIV, hepatitis virus (A, B, C, and D), VZV, HSV-I, HAV-6, HSV-II, CMV, Epstein Barr virus, adenovirus, influenza virus, flaviviruses, echovirus, rhinovirus, coxsackie virus, coronavirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus, arboviral encephalitis virus, SARS-CoV, MERS, and SARS-CoV-2.

16. The compound for use~~method~~ of claim 13, wherein the ~~method~~ use is for treating or preventing cancer.

17. The compound for use~~method~~ of claim 16, wherein the cancer is selected from the group consisting of osteosarcoma, rhabdomyosarcoma, neuroblastoma, kidney cancer, leukemia, renal transitional cell cancer, bladder cancer, Wilm's cancer, ovarian cancer, pancreatic cancer, breast cancer, prostate cancer, bone cancer, lung cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, cervical cancer, synovial sarcoma, head and neck cancer, squamous cell carcinoma, multiple myeloma, renal cell cancer, retinoblastoma, hepatoblastoma, hepatocellular carcinoma, melanoma, rhabdoid tumor of the kidney, Ewing's sarcoma, chondrosarcoma, brain cancer, glioblastoma, meningioma, pituitary adenoma, vestibular schwannoma, a primitive

neuroectodermal tumor, medulloblastoma, astrocytoma, anaplastic astrocytoma, oligodendroglioma, ependymoma, choroid plexus papilloma, polycythemia vera, thrombocythemia, idiopathic myelfibrosis, soft tissue sarcoma, thyroid cancer, endometrial cancer, carcinoid cancer, liver cancer, breast cancer, and gastric cancer.

18. The compound for use~~method~~ of claim 13, further comprising ~~the administration of~~ one or more additional agents, wherein the one or more agents are each independently an immune checkpoint inhibitor, an OX40 agonist, a 4-1BB agonist, an ICOS agonist, a GITR agonist, an IL-2-receptor agonist, or an antibody mediated by ADCC.

19. The ~~method~~ compound for use of claim 18, wherein the one or more agents are each independently an inhibitor of PD-1, PD-L1, CTLA4, TIM3, LAG3, SIRPα or CD47.

20. The ~~method~~ compound for use of claim 13, further~~ compsrising~~ comprising ~~the administration of~~ one or more additional agents, wherein the one or more additional agents are each independently a small-molecule therapeutic agent, a protein or peptide therapeutic, an antibody, sera from persons that have recovered from a viral infection, or a therapeutic or ~~preventitive~~ preventative vaccine.